This is different from other well-established fusions such as BCR-ABL in chronic myelogenous leukemia, TMPRSS2-ERG in prostate cancer, or EWS-FLI1 in Ewing’s sarcoma with junctional variability. This evidence concerns the gene TMPRSS2 and prostate carcinoma.